Phaseline

Companies › Shanghai Auzone Biological Technology

Shanghai Auzone Biological Technology: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Neurology, Psychiatry; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TTYP01 Tablets–Phase 2Autism Spectrum Disorder (ASD); ADOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06757504TTYP01 TabletsPhase 2Autism Spectrum Disorder (ASD)PsychiatryFeb 2026
NCT07252440TTYP01 TabletsPhase 2ADNeurologyOct 2028

From the company's SEC filings

Complete response letters from FDA

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Spinogenix Reunion Neuroscience TrueBinding Noema Pharma MapLight Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.